statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the...

Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the...

Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology

Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that MSCI...

EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases

Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD...

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimers Disease

Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimers Drug Discovery Foundation (ADDF)

Coya Therapeutics, Inc. (Nasdaq: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the...

Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results

Coya Therapeutics, Inc. (Nasdaq: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate...

Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Coya Therapeutics, Inc. (Nasdaq: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr...

Coya Therapeutics to Participate in the Mizuho Neuroscience Summit

Coya Therapeutics, Inc. (Nasdaq: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief...

Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.

Volume	41,988.00
52-Wk High	$10.69
52-Wk Low	$3.21

COYA Coya Therapeutics Inc

About

Feed

News

Fundamentals